Evidence map›Paper›PMID 39056047›Full record

ArticleJCEM case reports2024

Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic

Yu Ito, Toshinori Imaizumi, Hisashi Daido, Takehiro Kato, Daisuke Yabe

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCEM case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu ItoDepartment of Diabetes and Endocrinology, Gifu Prefectural General Medical Center, Gifu 500-8717, Japan.ORCID https://orcid.org/0009-0000-8785-1294
Toshinori ImaizumiDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.ORCID https://orcid.org/0000-0001-8808-1893
Hisashi DaidoDepartment of Diabetes and Endocrinology, Gifu Prefectural General Medical Center, Gifu 500-8717, Japan.ORCID https://orcid.org/0000-0002-2052-1714
Takehiro KatoDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.ORCID https://orcid.org/0000-0003-3236-2463
Daisuke YabeDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.ORCID https://orcid.org/0000-0002-5334-7687

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parathyroid carcinoma (PC) is extremely rare and is primarily treated surgically. Chemotherapy is an option for advanced stages, but no standard regimen exists. Emerging research suggests the efficacy of multitarget tyrosine kinase inhibitors (MTKIs) for PC, targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). A 61-year-old Japanese woman presented with a neck mass, diagnosed as PC with pleural and lumbar metastases. After parathyroidectomy and radiation for lumbar metastasis, immunohistochemistry showed VEGFR overexpression, leading to targeted therapy with MTKIs. Despite no actionable mutations on cancer genomic panel test, a novel

Indexed as

MEN1multi-target tyrosine kinase inhibitorsparathyroid carcinomaVEGF receptor

Identifiers

PMID39056047
PMCPMC11267463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.